



Biochemical Pharmacology, Volume 78, issue 11, 1 December 2009

Contents


COMMENTARY

Mechanisms of anti-cancer action and pharmacology of clofarabine

1351–1359

Anna Zhenchuk, Koroush Lotfi, Gunnar Juliusson, Freidoun Albertioni


Clofarabine's mechanism of action. Upon entering the cell, clofarabine is phosphorylated stepwise by deoxycytidine kinase (dCK), monophosphate kinase (MPkinase), and diphosphate kinase (DPkinase) to its triphosphate active form (clofarabineTP). ClofarabineTP acts as an inhibitor of DNA polymerase- α (DMA pol α) and - ϵ (DNA pol ϵ) by competing with the natural substrate dATP. When incorporated into DNA clofarabine leads to DNA damage, which signals activation or apoptotic pathways. It can further inhibit ribonucleotide reductase (RR), causing dNTP pool reduction and thus reinforcing its own incorporation into DNA. By directly affecting the mitochondrial transmembrane potential, clofarabine releases cytochrome c and apoptosis-inducing factor (AIF).



Commentary: Genome-based CNS drug discovery: D-Amino acid oxidase (DAAO) as a novel target for antipsychotic medications: Progress and challenges

1360–1365

Michael Williams



D-amino-acid oxidase


Image Courtesy of Wikipedia
http://en.wikipedia.org/w/index.php?title=D-amino_acid_oxidase&oldid=290829578

ANTIBIOTICS AND CHEMOTHERAPEUTICS

Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy

1366–1373


Dirk Theile, Sina Grebhardt, Walter Emil Haefeli, Johanna Weiss



Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma

1374–1381

Ilaria De Stefano, Giuseppina Raspaglio, Gian Franco Zannoni, Daniele Travaglia, Maria Grazia Prisco, Marco Mosca, Cristiano Ferlini, Giovanni Scambia, Daniela Gallo




INFLAMMATION AND IMMUNOPHARMACOLOGY

Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site

1382–1390

Philip E. Boulais, Dominic Dulude, Jérôme Cabana, Nikolaus Heveker, Emanuel Escher, Pierre Lavigne, Richard Leduc




METABOLIC DISORDERS AND ENDOCRINOLOGY

Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice

1391–1400

Florence M. Sohet, Audrey M. Neyrinck, Barbara D. Pachikian, Fabienne C. de Backer, Laure B. Bindels, Petra Niklowitz, Thomas Menke, Patrice D. Cani, Nathalie M. Delzenne




NEUROPHARMACOLOGY

Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems

1401–1411

Jing Ji, Mélanie Bourque, Thérèse Di Paolo, Dean E. Dluzen




PHARMACOKINETICS AND DRUG METABOLISM

TCP-FA4: A derivative of tranylcypromine showing improved blood–brain permeability

1412–1417

Kelly E. Desino, Rosario Pignatello, Salvatore Guccione, Livia Basile, Sabah Ansar, Mary Lou Michaelis, Rona R. Ramsay, Kenneth L. Audus

Derivatives of TCP containing FA or LAA moieties of varying side alkyl chain length were synthesized in an attempt to improve BBB permeability, by increasing the lipophilicity as well as amphiphatic character of the drug molecule. Results suggested that LAA promoiety containing medium to long side alkyl chains would be most useful in improving the permeability and membrane interaction of these compounds. TCP-FA4 may possess neuroprotective properties.



INDEXED/ABSTRACTED IN: *Curr. Cont. ASCA, Biosis Data, CAB Inter., Chemical Abstracts Service, Curr. Cont./Life Sci., CABS, EMBASE/Excerpt. Med., Curr. Cont. ISI/BIOMED Database, MEDLINE, PASCAL-CNRS Data, Curr. Cont. Sci. Cit. Ind., Curr. Cont. SCISEARCH Data, Ind. Med., Reference Update.*
 Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.



ELSEVIER

Available online at

ScienceDirect

www.elsevier.com/locate/biochempharm